120
Views
44
CrossRef citations to date
0
Altmetric
Original Article: GI Cancer

Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas

, , , , &
Pages 198-205 | Received 24 Mar 2004, Accepted 11 Aug 2004, Published online: 08 Jul 2009
 

Abstract

Objective Peroxisome proliferator-activated receptor (PPAR) ligands, widely used in type 2 diabetes treatment, have variably been shown to promote or prevent colon tumor formation in animal models and cell lines, but their role in normal human colon is unknown. The aim of this study was to determine PPARδ expression and function in normal human colonic epithelial cells and tubular adenomas.

Material and methods Short-term cultures of normal human colonic epithelial cells were established from biopsies obtained in 42 patients with normal colonoscopy. PPAR and adipophilin mRNA expression was assessed by real-time RT-PCR. PPARs were activated by ligands for PPARα (Wy-14643), PPARδ (GW-501516) and PPARγ (rosiglitazone or troglitazone). Cell viability was measured using the methyltetrazoleum assay, proliferation by thymidine incorporation, and DNA profiles by flow cytometry. PPAR mRNA levels in tubular adenomas or metaplastic polyps (n=12) were compared with those in controls.

Results PPARα and γ were consistently expressed in normal colonocytes while no PPAR expression could be detected. PPARγ activation induced a 7.5-fold increase in adipophilin expression (a PPAR-activated gene). PPARγ activation had no effect on viability or DNA profiles, but led to a 25% significant decrease in cell proliferation. Finally, a selective and significant 2.5-fold decrease in PPARα expression was observed in tubular adenomas, but not in metaplastic polyps, compared to controls.

Conclusions Our findings support the view that PPARγ ligands act as anti-proliferative agents rather than as promoters of tumorigenesis in normal human colon. Moreover, they raise interest in investigation of PPARα as a therapeutic target to prevent adenoma formation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.